Bifogade filer
Acarix shares begin trading on the US-based OTCQB Market
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce that the Acarix shares (OTCQB: ACIXF) begin trading today on the OTCQB Market in the US. Acarix´s shares will in parallel to its current Nasdaq First North Growth market listing in Stockholm, be traded with a US ticker symbol and a share price in USD.
OTC Markets Group operates financial markets for 12,000 US and global securities. OTCQB is a trading platform in the US operated by the OTC Markets Group, as an alternative to listing on Nasdaq New York and NYSE. Cross-trading on OTCQB helps satisfy an increasing interest from US investors and increase accessibility to the US capital market. Companies on OTCQB meet high financial standards, follow best practice corporate governance, demonstrate compliance with US securities laws, and have a professional third-party sponsor introduction.
“We’re excited to begin trading on the OTCQB Market in the US and expand the reach beyond our Nasdaq Stockholm listing. Acarix has a strong base of international shareholders and with the US being our most important commercial market, we now welcome the ability for more investors to join our journey”, comments Aamir Mahmood, CEO of Acarix.
“We are pleased to welcome Acarix to the OTCQB Best Market,” said Joe Coveney, Vice President of OTC Market Group’s Corporate Services. “Acarix will trade alongside other leading life science and medical device companies that utilize a ‘list local, trade global’ strategy to leverage their home market filings and disclosures to publicly trade in the US and expand their global investor base.”